Eighth World Congress on Alternatives and
Animal Use in the Life Sciences
August 21-25, 2011
Montreal, Canada
View printable list of NICEATM-ICCVAM activities, organized chronologically [PDF]
Theme I: Safety and Efficacy Testing of Chemicals, Pharmaceuticals and Biologicals
Platform Presentations
Session I-18: Report on the ICCVAM International Workshop on Vaccines:
ICCVAM Biologics Working Group
Dr. William Stokes, NICEATM Director, was chair of the session
ICCVAM Committee members Dr. Richard McFarland (U.S. FDA) and Dr. Jodie Kulpa-Eddy (USDA; ICCVAM Chair) presented
Session I-7:
Potency and safety testing of veterinary vaccines
ICCVAM Committee member Dr. Jodie Kulpa-Eddy (USDA; ICCVAM Chair) presented
Session I-8:
Safety testing for chemically-induced eye injuries: recent Three Rs advances
ICCVAM Committee member Dr. Jack Fowle (EPA) presented
Session I-3:
Biological and biotechnology-based therapeutics
ICCVAM Committee member Dr. Ying Huang (FDA) presented
Session I-4: Validation of Alternative Test Methods for
Detecting Estrogen Active Substances: Impact on the Three Rs
Dr. Warren Casey, NICEATM Deputy Director, was co-chair of the session
Dr. Casey and ICCVAM Committee member Dr. Jack Fowle (EPA) presented
Abstract : BG1Luc ER TA Test Method: Results of an
International Validation Study and Proposed Performance Standards
Author: W Casey
View abstract [PDF]
Session I-13: Toxicity testing in the 21st century
ICCVAM working group member Dr. Ray Tice (NIEHS) presented
Session I-5: Nanotechnology and the Three Rs
ICCVAM Committee Member Dr. Abby Jacobs (FDA) presented
Session I-17: Update on New In Vitro Models for Detection and
Potency Assessment of Botulinum Neurotoxin
Dr. Warren Casey, NICEATM Deputy Director, was co-chair of the session
Poster Presentations
Abstract I-11-575: International Acceptance of the Nonradioactive LLNA: DA for Evaluating
Allergic Contact Dermatitis Hazards
Authors: P Brown, J Matheson, A Jacobs, R Ward, E Margosches, E Salicru, D Allen, F Stack, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-11-574: International Acceptance of the Nonradioactive LLNA:
BrdU-ELISA for Evaluating Allergic Contact Dermatitis Hazards
Authors: A Jacobs, J Matheson, V Malshet, J Toy, J Strickland, D Allen, T Burns, F Stack, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-8-576:Usefulness and Limitations of the Cytosensor Microphysiometer Test Method for Ocular Safety Testing
Authors: W Stokes, D Lowther, A Layton, J Redden, E Lipscomb, J Truax, N Johnson, D Allen
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-1-569: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Human Vaccine Potency and Safety Testing
Authors: R McFarland, J Kulpa-Eddy , R Isbrucker, M Halder, H Kojima, D Verthelyi,
M Schmitt, R Levis, N Johnson, B Jones, D Allen, W Casey, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-1-570: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of
Animals in Veterinary Vaccine Potency and Safety Testing
Authors: J Kulpa-Eddy, R McFarland, R Isbrucker, M Halder, H Kojima, G Srinivas, K Brown,
B Jones, N Johnson, D Allen, W Casey, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-11-567: Evaluation of the Murine Local Lymph Node Assay (LLNA) for Potency Categorization
of Chemicals Causing Allergic Contact Dermatitis in Humans
Authors: J Strickland, P Brown, J Matheson, A Jacobs, T McMahon, D Germolec, D Allen,
E Salicru, T Burns, F Stack, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-11-568: Evaluation of the Murine Local Lymph Node Assay (LLNA) for Assessing the Allergic
Contact Dermatitis Hazard Potential of Pesticide Formulations
Authors: T McMahon, D McCall, J Matheson, A Jacobs, T Burns, D Allen, W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Abstract I-11-446: Updated NICEATM Evaluation and International
Acceptance of the Reduced Murine Local Lymph Node Assay
Authors: D Allen, T Burns, J Strickland, E Salicru, and W Stokes
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Theme II: Policy/Law on Animal Use, Public Engagement and Ethics Review
Platform Presentations
Session II-1:
Public accountability
ICCVAM Committee member Dr. Suzanne Fitzpatrick (FDA) was co-chair of the session
Session II-5: Validation of Three Rs Alternative Methods
Dr. William Stokes, NICEATM Director, was co-chair of the session
Abstract II-5-561: Validation of the 21st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward
Author: W Stokes
View abstract [PDF]
Session II-11: The International cooperation on alternative test methods (ICATM)
(updates from the National Validation Centers)
Dr. William Stokes, NICEATM Director, was chair of the session and also presented
Theme IV: Animal Welfare for Refinement and High Quality Science
Poster Presentation
Abstract IV-1-292: Eliminating Pain and Distress in Ocular Safety Testing: Use of Topical
Anesthetics, Systemic Analgesics, and Humane Endpoints
Authors: W Stokes, J Merrill, D Lowther, T McMahon, J Chen, M Hashim, M Lewis, B Jones, E Lipscomb, D Allen
View abstract [PDF]
View poster [PDF]
View text version of poster — may provide greater accessibility [PDF]
Theme V: Replacement and Reduction in Basic Research
Platform Presentations
Session II-1:
Relevance, Reproducibility and Robustness – the other Three Rs important to science and animal welfare
ICCVAM working group member Dr. Myrtle Davis (NCI) was co-chair of the session
Session II-5: Validation of Three Rs Alternative Methods
Dr. William Stokes, NICEATM Director, was co-chair of the session
|
